You just read:

Results from Genelux Corporation's Phase 1b Trial of GL-ONC1 in Recurrent Ovarian Cancer to be presented at the ASCO Annual Meeting 2018

News provided by

Genelux Corporation

Jun 04, 2018, 07:07 ET